TECENTRIQ + COTELLIC + ZELBORAF
A combination of atezolizumab, cobimetinib, and vemurafenib (Genentech) used in BRAF-mutant melanoma.
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and TECENTRIQ + COTELLIC + ZELBORAF. Select a testing pathway to see the eligible companion diagnostic tests.
Approvals where TECENTRIQ + COTELLIC + ZELBORAF is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Melanoma Solid Tumor · Melanoma | BRAF
| View testing pathway → |
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for TECENTRIQ + COTELLIC + ZELBORAF.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering TECENTRIQ + COTELLIC + ZELBORAF for eligible patients.